全文获取类型
收费全文 | 6987篇 |
免费 | 426篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 189篇 |
妇产科学 | 78篇 |
基础医学 | 963篇 |
口腔科学 | 116篇 |
临床医学 | 446篇 |
内科学 | 1834篇 |
皮肤病学 | 94篇 |
神经病学 | 490篇 |
特种医学 | 272篇 |
外科学 | 1272篇 |
综合类 | 44篇 |
一般理论 | 2篇 |
预防医学 | 215篇 |
眼科学 | 198篇 |
药学 | 317篇 |
中国医学 | 10篇 |
肿瘤学 | 854篇 |
出版年
2023年 | 73篇 |
2022年 | 56篇 |
2021年 | 269篇 |
2020年 | 148篇 |
2019年 | 180篇 |
2018年 | 260篇 |
2017年 | 177篇 |
2016年 | 197篇 |
2015年 | 182篇 |
2014年 | 261篇 |
2013年 | 321篇 |
2012年 | 478篇 |
2011年 | 471篇 |
2010年 | 255篇 |
2009年 | 215篇 |
2008年 | 405篇 |
2007年 | 370篇 |
2006年 | 320篇 |
2005年 | 383篇 |
2004年 | 395篇 |
2003年 | 311篇 |
2002年 | 273篇 |
2001年 | 141篇 |
2000年 | 102篇 |
1999年 | 100篇 |
1998年 | 50篇 |
1997年 | 52篇 |
1996年 | 34篇 |
1995年 | 35篇 |
1994年 | 36篇 |
1993年 | 24篇 |
1992年 | 71篇 |
1991年 | 71篇 |
1990年 | 66篇 |
1989年 | 81篇 |
1988年 | 86篇 |
1987年 | 52篇 |
1986年 | 52篇 |
1985年 | 50篇 |
1984年 | 37篇 |
1983年 | 30篇 |
1982年 | 21篇 |
1981年 | 22篇 |
1980年 | 17篇 |
1979年 | 30篇 |
1978年 | 15篇 |
1975年 | 22篇 |
1972年 | 20篇 |
1971年 | 18篇 |
1970年 | 16篇 |
排序方式: 共有7458条查询结果,搜索用时 31 毫秒
1.
2.
Daisuke Yamamoto Kou Kayamori Kei Sakamoto Maiko Tsuchiya Tohru Ikeda Hiroyuki Harada Tetsuya Yoda Tetsuro Watabe Miki Hara‐Yokoyama 《Cancer science》2020,111(2):700-712
Claudins are the major component of tight junctions, which form a primary barrier to paracellular diffusion and maintain cell polarity in normal epithelia and endothelia. In cancer cells, claudins play additional roles besides serving as components of the tight junctions, and participate in anoikis or invasion. Among the claudin family proteins, claudin‐1 has the most promising potential, both diagnostically and prognostically, in many types of cancers, including oral, gastric, liver, and colon cancers. However, conflicting results have been reported in relation to the degree of claudin‐1 expression and the prognosis, suggesting that the expression level of claudin‐1 alone is not sufficient to analyze the relationship between claudin‐1 and cancer progression. As endocytic trafficking of claudin‐1 has been reported in several epithelial cell types in vitro, we aimed to determine whether intracellular localization of claudin‐1 is the missing aspect between claudin‐1 and cancer. We investigated the expression of claudin‐1 in 83 tongue squamous cell carcinoma (TSCC) pathological specimens. Although the expression level of claudin‐1 based on immunohistochemistry was not associated with TSCC progression, within the high claudin‐1 expression group, the incidence of intracellular localization of claudin‐1 was correlated with cervical lymph node metastasis. In an in vitro experiment, claudin‐1 was constitutively internalized in TSCC‐derived cells. Motility of TSCC‐derived cells was increased by deficiency of claudin‐1, suggesting that the decrease in cell‐surface claudin‐1 promoted the cell migration. Therefore, intracellular localization of claudin‐1 at the invasion front may represent a promising diagnostic marker of TSCC. 相似文献
3.
Stefano Cascinu György Bodoky Kei Muro Eric Van Cutsem Sang Cheul Oh Gunnar Folprecht Sumitra Ananda Gustavo Girotto Zev A. Wainberg Maria Luisa Limon Miron Jaffer Ajani Ran Wei Astra M. Liepa Roberto Carlesi Michael Emig Atsushi Ohtsu 《The oncologist》2021,26(3):e414-e424
BackgroundIn the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation.Materials and MethodsTumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐Core 30 (EORTC QLQ‐C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR.ResultsIn both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation.ConclusionTreatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. .Implications for PracticeRamucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first‐line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits. NCT01170663相似文献
4.
5.
Shota Nukaga Takuya Mori Yoshihiro Miyagawa Rina FujiwaraTani Takamitsu Sasaki Kiyomu Fujii Shiori Mori Kei Goto Shingo Kishi Chie Nakashima Hitoshi Ohmori Isao Kawahara Yi Luo Hiroki Kuniyasu 《Cancer science》2020,111(12):4605
Cancer‐derived myocardial damage is an important cause of death in cancer patients. However, the development of dietary interventions for treating such damage has not been advanced. Here, we investigated the effect of dietary intervention with lauric acid (LAA) and glucose, which was effective against skeletal muscle sarcopenia in a mouse cachexia model, on myocardial damage. Treatment of H9c2 rat cardiomyoblasts with lauric acid promoted mitochondrial respiration and increased ATP production by Seahorse flux analysis, but did not increase oxidative stress. Glycolysis was also promoted by LAA. In contrast, mitochondrial respiration and ATP production were suppressed, and oxidative stress was increased in an in vitro cachexia model in which cardiomyoblasts were treated with mouse cachexia ascites. Ascites‐treated H9c2 cells with concurrent treatment with LAA and high glucose showed that mitochondrial respiration and glycolysis were promoted more than that of the control, and ATP was restored to the level of the control. Oxidative stress was also reduced by the combined treatment. In the mouse cachexia model, myocardiac atrophy and decreased levels of a marker of muscle maturity, SDS‐soluble MYL1, were observed. When LAA in CE‐2 diet was orally administered alone, no significant rescue was observed in the cancer‐derived myocardial disorder. In contrast, combined oral administration of LAA and glucose recovered myocardial atrophy and MYL1 to levels observed in the control without increase in the cancer weight. Therefore, it is suggested that dietary intervention using a combination of LAA and glucose for cancer cachexia might improve cancer‐derived myocardial damage. 相似文献
6.
Naoko Uetsu Yuki Nomura Yoshie Matsuyama Hiroyuki Okamoto 《The Journal of dermatology》2020,47(4):369-377
Solar urticaria has unique spectra, such as inhibition and augmentation. The clinical significance of these spectra, especially augmentation, is not well understood. Reported cases of solar urticaria with augmentation spectra are extremely rare in the published English-language work. The purposes of this study were to evaluate the clinical features of solar urticaria with augmentation spectra and to elucidate the mechanisms and clinical importance of the spectra. We experienced 11 cases (five females, six males; mean age, 40.1 years; range, 1–74) of solar urticaria with augmentation spectra from April 2007 to July 2019. Augmentation spectra were UV-B in three cases, UV-A in two, visible light in four, UV-A and UV-B in one, and UV-A and visible light in one. Augmentation spectra were observed before action spectra in four cases, after in six, and before and after in one. Injection of sera irradiated with action spectra and augmentation spectra in vitro induced stronger immediate reactions than those of only action spectrum-irradiated sera in four of five cases. The results of injection tests suggested that augmentation spectra enhance the production of urticaria-forming factor. Clinically, we observed severe urticarial reactions in four cases, including anaphylaxis in three and moderate urticarial reactions in three. These results suggest that augmentation spectra are not as rare as previously thought and that they are associated with the severity of solar urticaria. Therefore, phototesting for both augmentation and action spectra should be performed to provide appropriate guidance for patients with solar urticaria. 相似文献
7.
Andrew R. Lavik Fei Zhong Ming-Jin Chang Edward Greenberg Yuvraj Choudhary Mitchell R. Smith Karen S. McColl John Pink Frederic J. Reu Shigemi Matsuyama Clark W. Distelhorst 《Oncotarget》2015,6(29):27388-27402
Bcl-2 inhibits apoptosis by two distinct mechanisms but only one is targeted to treat Bcl-2-positive malignancies. In this mechanism, the BH1-3 domains of Bcl-2 form a hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, including Bim. In the other mechanism, the BH4 domain mediates interaction of Bcl-2 with inositol 1,4, 5-trisphosphate receptors (IP3Rs), inhibiting pro-apoptotic Ca2+ signals. The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton’s tyrosine kinase inhibitor Ibrutinib. Moreover, combining BIRD-2 with ABT-263 or ABT-199 enhances apoptosis induction compared to single agent treatment. Overall, these findings provide strong rationale for developing novel therapeutic agents that mimic the action of BIRD-2 in targeting the BH4 domain of Bcl-2 and disrupting Bcl-2-IP3R interaction. 相似文献
8.
9.
‘Let's talk about sex’ – A Knowledge,Attitudes and Practice study among Paediatric Nurses about Teen Sexual Health in Hong Kong 下载免费PDF全文